title: A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections.
abstract: A 73-year-old woman with malignant insulinoma was treated with 100 μg/day octreotide for unresected insulinoma and liver metastases. The daily administration of the drug induced hyperglycemia after dinner in addition to existing fasting hypoglycemia possibly because this drug suppressed both insulin and glucagon secretion and its blood concentration was unstable. After replacing a daily injection of octreotide with a monthly injection of octreotide long-acting repeatable (LAR), blood glucose levels stabilized within the normal range. The findings of the present study showed that octreotide LAR could be useful for the long-term treatment of unresectable insulinomas.
authors.affiliation: Department of Diabetes and Metabolic Medicine, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Okamoto
authors.forename: Miyako
authors.initials: M
authors.lastname: Kishimoto
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Osame
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Noto
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Yamamoto-Honda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kajio
authors.forename: Makoto
authors.initials: M
authors.lastname: Tokuhara
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Edamoto
authors.forename: Hisako
authors.initials: H
authors.lastname: Endo
authors.forename: Toru
authors.initials: T
authors.lastname: Igari
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kubota
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Noda
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007340:Insulinoma / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D015282:Octreotide